131 related articles for article (PubMed ID: 36828805)
1. Applying a risk prediction model for bloodstream infection in a febrile, nonseverely neutropenic cohort of pediatric stem cell transplant patients.
Jackson K; Anderson V; Zhao Z; Kitko CL; Connelly JA; Ho RH; Banerjee R; Dulek DE; Friedman DL; Esbenshade AJ
Cancer; 2023 May; 129(10):1591-1601. PubMed ID: 36828805
[TBL] [Abstract][Full Text] [Related]
2. Prospective Implementation of a Risk Prediction Model for Bloodstream Infection Safely Reduces Antibiotic Usage in Febrile Pediatric Cancer Patients Without Severe Neutropenia.
Esbenshade AJ; Zhao Z; Baird A; Holmes EA; Dulek DE; Banerjee R; Friedman DL
J Clin Oncol; 2020 Sep; 38(27):3150-3160. PubMed ID: 32762614
[TBL] [Abstract][Full Text] [Related]
3. Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer.
Zhao Z; Patel PA; Slatnick L; Sitthi-Amorn A; Bielamowicz KJ; Nunez FA; Walsh AM; Hess J; Rossoff J; Elgarten C; Myers R; Saab R; Basbous M; Mccormick M; Aftandilian C; Richards R; Nessle CN; Tribble AC; Sheth Bhutada JK; Coven SL; Runco D; Wilkes J; Gurunathan A; Guinipero T; Belsky JA; Lee K; Wong V; Malhotra M; Armstrong A; Jerkins LP; Cross SJ; Fisher L; Stein MT; Wu NL; Yi T; Orgel E; Haeusler GM; Wolf J; Demedis JM; Miller TP; Esbenshade AJ
J Clin Oncol; 2024 Mar; 42(7):832-841. PubMed ID: 38060973
[TBL] [Abstract][Full Text] [Related]
4. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia.
Esbenshade AJ; Zhao Z; Aftandilian C; Saab R; Wattier RL; Beauchemin M; Miller TP; Wilkes JJ; Kelly MJ; Fernbach A; Jeng M; Schwartz CL; Dvorak CC; Shyr Y; Moons KGM; Sulis ML; Friedman DL
Cancer; 2017 Oct; 123(19):3781-3790. PubMed ID: 28542918
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.
Ziegler M; Landsburg D; Pegues D; Bilker W; Gilmar C; Kucharczuk C; Gorman T; Bink K; Moore A; Fitzpatrick R; Stadtmauer EA; Mangan P; Kraus K; Han JH
Biol Blood Marrow Transplant; 2019 May; 25(5):1004-1010. PubMed ID: 30481595
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a prediction model for diagnosing blood stream infections in febrile, non-neutropenic children with cancer.
Esbenshade AJ; Pentima MC; Zhao Z; Shintani A; Esbenshade JC; Simpson ME; Montgomery KC; Lindell RB; Lee H; Wallace A; Garcia KL; Moons KG; Friedman DL
Pediatr Blood Cancer; 2015 Feb; 62(2):262-268. PubMed ID: 25327666
[TBL] [Abstract][Full Text] [Related]
7. Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Ali N; Adil SN; Shaikh MU
Transpl Infect Dis; 2014 Feb; 16(1):98-105. PubMed ID: 24383473
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation.
Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G
Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.
Burdach S; van Kaick B; Laws HJ; Ahrens S; Haase R; Körholz D; Pape H; Dunst J; Kahn T; Willers R; Engel B; Dirksen U; Kramm C; Nürnberger W; Heyll A; Ladenstein R; Gadner H; Jürgens H; Go el U
Ann Oncol; 2000 Nov; 11(11):1451-62. PubMed ID: 11142486
[TBL] [Abstract][Full Text] [Related]
10. Febrile Neutropenia Syndromes in Children: Risk Factors and Outcomes of Primary, Prolonged, and Recurrent Fever.
Alali M; David MZ; Ham SA; Danziger-Isakov L; Pisano J
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e962-e971. PubMed ID: 34133386
[TBL] [Abstract][Full Text] [Related]
11. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
12. Initially fewer bloodstream infections for allogeneic vs. autologous stem-cell transplants in neutropenic patients.
Hieke S; Bertz H; Dettenkofer M; Schumacher M; Beyersmann J
Epidemiol Infect; 2013 Jan; 141(1):158-64. PubMed ID: 22394546
[TBL] [Abstract][Full Text] [Related]
13. D-index as a marker of bloodstream infections in patients with allogeneic hematopoietic stem cell transplantation.
Vijayvargiya P; Lara Abad C; Esquer Garrigos Z; O'Horo JC; Walker RC; Hogan WJ; Tande AJ
Transpl Infect Dis; 2021 Aug; 23(4):e13588. PubMed ID: 33590904
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project.
Dettenkofer M; Wenzler-Röttele S; Babikir R; Bertz H; Ebner W; Meyer E; Rüden H; Gastmeier P; Daschner FD;
Clin Infect Dis; 2005 Apr; 40(7):926-31. PubMed ID: 15824981
[TBL] [Abstract][Full Text] [Related]
15. Non-neutropenic fever in children with cancer: Management, outcomes and clinical decision rule validation.
Walker H; Esbenshade AJ; Dale S; Bhatia K; Zhao Z; Babl FE; Conyers R; Haeusler GM
Pediatr Blood Cancer; 2022 Dec; 69(12):e29931. PubMed ID: 36031722
[TBL] [Abstract][Full Text] [Related]
16. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.
Shimoni A; Hardan I; Avigdor A; Yeshurun M; Raanani P; Ben-Bassat I; Nagler A
Br J Haematol; 2003 Aug; 122(3):457-64. PubMed ID: 12877674
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors, and outcome of blood stream infections during the first 100 days post-pediatric allogeneic and autologous hematopoietic stem cell transplantations.
Youssef A; Hafez H; Madney Y; Elanany M; Hassanain O; Lehmann LE; El Haddad A
Pediatr Transplant; 2020 Feb; 24(1):e13610. PubMed ID: 31682054
[TBL] [Abstract][Full Text] [Related]
19. Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies.
Yun S; Vincelette ND; Abraham I; Puvvada S; Anwer F
Acta Haematol; 2016; 136(4):244-255. PubMed ID: 27802434
[TBL] [Abstract][Full Text] [Related]
20. Association Between Depth of Neutropenia and Clinical Outcomes in Febrile Pediatric Cancer and/or Patients Undergoing Hematopoietic Stem-cell Transplantation.
Alali M; David MZ; Danziger-Isakov LA; Bartlett AH; Petty LA; Schwartz T; Pisano J
Pediatr Infect Dis J; 2020 Jul; 39(7):628-633. PubMed ID: 32176187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
